文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

重组人可溶性血栓调节蛋白与脓毒症合并严重呼吸衰竭患者死亡率降低相关:基于多中心数据集的回顾性观察研究

Recombinant Human-Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients With Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset.
PubMed 文献 · Shock · 2019-01-01
一句话结论在脓毒症合并严重呼吸衰竭患者中,使用重组人可溶性血栓调节蛋白与ICU死亡率和住院死亡率降低相关,但为回顾性观察研究。

该研究利用日本42个ICU的既有数据集,回顾性纳入1180例脓毒症合并严重呼吸衰竭患者(rhTM组356例,无rhTM组824例),比较两组结局。倾向性评分匹配后生存时间分析显示两组有显著差异(HR 0.654,95%CI 0.439-0.974,P=0.03)。rhTM组ICU死亡率22.1%(33/149)低于无rhTM组36.2%(54/149),P=0.01;住院死亡率35.6%(53/149)低于49.7%(74/149),P=0.02;无呼吸机天数有升高趋势(12.8±10.1天 vs 10.6±10.6天,P=0.09)。作者结论认为rhTM给药与死亡率降低正相关。

要点

  • 倾向性评分匹配后,rhTM组与无rhTM组生存时间分析有显著差异(HR 0.654,95%CI 0.439-0.974,P=0.03)。
  • rhTM组ICU死亡率22.1%(33/149)低于无rhTM组36.2%(54/149),P=0.01。
  • rhTM组住院死亡率35.6%(53/149)低于无rhTM组49.7%(74/149),P=0.02。
  • 无呼吸机天数rhTM组12.8±10.1天,无rhTM组10.6±10.6天,P=0.09,仅为趋势。
  • 作者结论:rhTM给药与脓毒症合并严重呼吸衰竭患者死亡率降低正相关,为回顾性观察研究。

适用人群与场景

  • 日本42个ICU的严重脓毒症或脓毒症休克患者中,合并严重呼吸衰竭者;最终分析1180例(rhTM组356例,无rhTM组824例)。

研究设计与关键结果

  • 回顾性观察研究,利用日本42个ICU的既有数据集,从3195例严重脓毒症或脓毒症休克患者中选取合并严重呼吸衰竭者,按是否接受rhTM分为rhTM组(n=356)和无rhTM组(n=824),并进行倾向性评分分析。
  • 倾向性评分匹配后生存时间分析显示两组有显著差异(HR 0.654,95%CI 0.439-0.974,P=0.03)。
  • ICU死亡率rhTM组22.1%(33/149) vs 无rhTM组36.2%(54/149),P=0.01。
  • 住院死亡率rhTM组35.6%(53/149) vs 无rhTM组49.7%(74/149),P=0.02。
  • 无呼吸机天数rhTM组12.8±10.1天 vs 无rhTM组10.6±10.6天,P=0.09,仅为趋势。

证据类型、等级与局限

  • 证据类型:回顾性观察研究,使用多中心既有数据集(42个ICU)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为rhTM给药与脓毒症合并严重呼吸衰竭患者死亡率降低正相关,该结果为回顾性观察性研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recombinant human-soluble thrombomodulin (rhTM) is a novel class therapeutic agent for managing disseminated intravascular coagulation. The progression of severe respiratory failure may be related to intra-alveolar coagulation/fibrinolytic disorders. We aimed to determine the efficacy of rhTM in treating sepsis patients with severe respiratory failure.

METHODS: We performed a retrospective observational study using an existing dataset collected from 42 intensive care units (ICUs) in Japan. Of 3,195 patients with severe sepsis or septic shock from the dataset, we selected sepsis patients with severe respiratory failure, and compared patient outcomes based on the administration of rhTM (rhTM group and no rhTM group). Propensity score analysis was performed between the two groups. Outcomes of interest were ICU mortality, hospital mortality, and ventilator-free days (VFDs).

RESULTS: In this study, 1,180 patients (rhTM, n = 356; no rhTM, n = 824) were analyzed. After adjusting for baseline imbalances with propensity score matching, the survival-time analysis revealed a significant difference between the two groups (hazard ratio, 0.654; 95% confidence interval, 0.439-0.974, P = 0.03). ICU mortality was lower in the rhTM group (rhTM: 22.1% [33/149] vs. no rhTM: 36.2% [54/149], P = 0.01). Hospital mortality was also lower in the rhTM group (35.6% [53/149] vs. 49.7% [74/149], P = 0.02). VFDs trended to be higher in the rhTM group than the no rhTM group (12.8 ± 10.1 days vs. 10.6 ± 10.6 days, P = 0.09).

CONCLUSIONS: Administration of rhTM was positively correlated with a reduction in mortality in sepsis patients with severe respiratory failure.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Yoshihiro S, Sakuraya M, Hayakawa M, et al. Recombinant Human-Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients With Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset. Shock. 2019. PMID: 29596106. doi:10.1097/SHK.0000000000001148

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。